• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global EPO Biosimilars Market Outlook 2018 - Product Image

Global EPO Biosimilars Market Outlook 2018

  • ID: 2763976
  • February 2014
  • Region: Global
  • 45 Pages
  • RNCOS E-Services Private Limited


  • 3 SBio Inc
  • Biocon
  • Dr. Reddy's Labs (DRL)
  • Hexal AG
  • Hospira
  • Intas Pharmaceuticals
  • MORE

The biosimilars industry has been growing stupendously across the globe for the past few years. Increasing healthcare costs, major blockbuster drugs about to go off patent and rising aging population are driving this industry, which stands at a vivid position, and is expected to evolve greatly from its current state. With the governments and private players worldwide stepping into this industry, the market shows bright prospects and immense opportunities to cash in on.

As per the estimations of our latest report, “Global EPO Biosimilars Market Outlook 2018”, the global EPO biosimilars market will grow at a CAGR of around 37% during 2013-2018. Our report provides a thorough study of the EPO biosimilars market, and its future outlook. Firstly, we have provided a basic overview of the total biologics market, along with its current and future size. Next, we have highlighted some of the major trends and drivers which would be responsible for shaping the global biosimilars market. Some of these trends are rising collaborations among major pharma players and strong government support to encourage the growth of biosimilars. This is then followed by the total biosimilars market READ MORE >


  • 3 SBio Inc
  • Biocon
  • Dr. Reddy's Labs (DRL)
  • Hexal AG
  • Hospira
  • Intas Pharmaceuticals
  • MORE

1. Analyst View

2. Research Methodology

3. Biologics Market Outlook to 2018
3.1 Market Size
3.2 Market Segmentation

4. Market Trends & Drivers
4.1 Emerging Markets to Play a Pivotal Role in the Growth of Biosimilars
4.2 Rising Business Alliances Aiding in Biosimilar Development
4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth

5. Biosimilars Market Outlook to 2018

6. Erythropoietin Market Outlook to 2018
6.1 Scientific Insight
6.2 Market Analysis
6.3 EPO Biosimilars Products - Marketed and Under-Pipeline

7. Competitive Landscape
7.1 Hospira
7.2 Sandoz GmbH
7.3 Stada
7.4 Hexal AG
7.5 Medice Arzneimittel Pütter GmbH & Co.
7.6 Teva
7.7 LG Life Sciences
7.8 Dr. Reddy's Labs (DRL)
7.9 Biocon
7.10 Intas Pharmaceuticals
7.11 Reliance Life Sciences
7.12 3 SBio Inc

List of Tables
Table 6-1: Global - Marketed EPO Biosimilar Products of Key Players
Table 6-2: Global - Pipeline EPO Biosimilar Products of Key Players

List of Figures
Figure 3-1: Global - Biologics Market (Billion US$), 2012-2018
Figure 3-2: Global - Biologics Market by Segment (%), 2012
Figure 5-1: Global - Biosimilars Market (Billion US$), 2012 & 2018
Figure 5-2: Global - Biosimilars Market by Key Segment (%), 2012
Figure 6-1: Global - EPO Biosimilars Market (Billion US$), 2012-2018
Figure 6-2: Global - EPO Biosimilar Market by Player (%), 2012

-3 SBio Inc
-Dr. Reddy's Labs (DRL)
-Hexal AG
-Intas Pharmaceuticals
-LG Life Sciences
-Medice Arzneimittel Pütter GmbH & Co.
-Reliance Life Sciences
-Sandoz GmbH

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos